Moderna Outlines Future Growth Plans at Science Day
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 48 minutes ago
0mins
Source: Yahoo Finance
- Future Growth Strategy: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Stephane Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, showcasing the company's forward-looking approach in vaccine development.
- Cancer Pipeline Progress: Moderna highlighted mRNA-4106 and mRNA-4200 for advanced solid tumors, along with mRNA-4194 targeting Lynch syndrome, which is the company's first cancer prevention study aimed at training the immune system to recognize 194 cancer-linked frameshift peptides, indicating potential for early intervention.
- Multiple Sclerosis Research: The mRNA-1195 program targets the Epstein-Barr virus, closely linked to multiple sclerosis, with the Phase 2 study fully enrolling its first group of patients, and an independent safety board recommending moving to dose escalation, suggesting initial safety and efficacy have been recognized.
- Flu Vaccine Regulatory Progress: Moderna's flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, indicating that its benefits outweigh risks for adults aged 50 and older, which is expected to provide an important new option for seasonal flu prevention and further solidify the company's position in the vaccine market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 59.750
Low
17.00
Averages
32.47
High
63.00
Current: 59.750
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Outlines Future Growth Plans at Science Day
- Future Growth Strategy: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Stephane Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, showcasing the company's forward-looking approach in vaccine development.
- Cancer Pipeline Progress: Moderna highlighted mRNA-4106 and mRNA-4200 for advanced solid tumors, along with mRNA-4194 targeting Lynch syndrome, which is the company's first cancer prevention study aimed at training the immune system to recognize 194 cancer-linked frameshift peptides, indicating potential for early intervention.
- Multiple Sclerosis Research: The mRNA-1195 program targets the Epstein-Barr virus, closely linked to multiple sclerosis, with the Phase 2 study fully enrolling its first group of patients, and an independent safety board recommending moving to dose escalation, suggesting initial safety and efficacy have been recognized.
- Flu Vaccine Regulatory Progress: Moderna's flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, indicating that its benefits outweigh risks for adults aged 50 and older, which is expected to provide an important new option for seasonal flu prevention and further solidify the company's position in the vaccine market.
See More
Moderna Outlines Future Growth Plans at Science Day
- Vaccine Development Focus: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, laying a solid foundation for future product line expansion.
- mRED Strategy Implementation: Moderna's mRED strategy aims to quickly test early 'sentinel' programs, promptly halt ineffective drugs, and accelerate promising ones, ensuring swift decision-making during the high-risk clinical development phase, thereby enhancing R&D efficiency and mitigating risks.
- Significant Cancer Pipeline Progress: Moderna highlighted its mRNA projects targeting various cancers, including mRNA-4106 and mRNA-4200, particularly mRNA-4194 as its first cancer prevention program aimed at training the immune system to recognize cancer-linked peptides, showcasing strong market potential for early disease targeting.
- AI Technology Enhancing R&D: Moderna introduced its Scientific Intelligence Engine, Lucy, emphasizing the scientific advantage of rapid learning, while its flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, expected to provide an important new option for seasonal flu prevention, further strengthening the company's competitive position.
See More
Biotech Stocks Hit 52-Week Highs Amid Speculation and Trials
- Sellas Life Sciences Surge: Sellas Life Sciences' stock soared 17% to a 52-week high of $12.43 as record short interest and acquisition speculation fueled investor optimism, particularly ahead of a key update from its Phase 3 AML trial.
- Moderna's Pipeline Advances: Moderna's stock rose 12% to $69.29 following its Science Day presentation, where it showcased advancements in cancer, autoimmune, and rare disease therapies, emphasizing its strategic use of AI and automation in drug discovery.
- AbCellera's Major Partnership: AbCellera Biologics' stock climbed over 10% to a two-year high of $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market confidence in their T-cell engager antibody programs.
- Investor Sentiment Optimism: The closing highs for Sellas Life Sciences, Moderna, and AbCellera Biologics on Friday reflect robust investor confidence in biotech firms, particularly those with identifiable near-term clinical events and business catalysts.
See More
Sellas Life Sciences Hits 52-Week High Amid Buyout Speculation
- Stock Surge: Sellas Life Sciences' stock reached a 52-week high of $12.43 on Friday, driven by record short interest and rising acquisition speculation, reflecting strong investor confidence in the company.
- Clinical Trial Update: The company is approaching a key update for its acute myeloid leukemia (AML) clinical trial, with 78 patient deaths recorded, just shy of the final analysis, which is eagerly anticipated by investors.
- Moderna's Innovations: Moderna's stock climbed to $69.29 following its Science Day presentation, showcasing advancements in cancer, autoimmune, and rare disease therapies, while emphasizing its use of AI and automation in drug discovery, solidifying its market position.
- AbCellera Partnership: AbCellera Biologics' stock rose to $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market interest in its multispecific T-cell engager antibodies and potential future milestone payments.
See More
Moderna's Investor Day Sparks Surge in Stock Price
- Moderna Stock Surge: Moderna's stock has surged following its Investor Day, where the company outlined its future strategies beyond the COVID vaccine business, becoming a top performer in the S&P 500, indicating strong market confidence in its next-generation autoimmune disease treatments.
- Netflix Bounce Back: Netflix's stock is experiencing a relief bounce after hitting a 20-month low, as investors, despite concerns over competition and engagement, appear to be stepping back in, reflecting a reassessment of the company's growth potential.
- ON Semiconductor Acquisition: ON Semiconductor's shares are plummeting after announcing a nearly $7 billion all-stock deal to acquire Synaptics, aimed at expanding its push into physical AI, although investors are digesting the implications of this significant acquisition.
- Market Reaction Insights: The stock movements of Moderna and Netflix illustrate differing investor sentiments regarding future strategies, highlighting the critical importance of how companies adapt their business models to navigate current economic challenges.
See More
Moderna Shares Surge 42% as Company Expands Beyond COVID Vaccines
- Stock Surge: Moderna shares surged nearly 15% on Friday to around $69, marking a 42% increase over the past month, significantly outperforming the S&P 500's 7.49% return, reflecting strong market confidence in its future prospects.
- Diversification Strategy: During its Science Day event, Moderna highlighted progress in cancer treatments, autoimmune diseases, and next-generation mRNA medicines, indicating its commitment to becoming a diversified drug developer beyond COVID vaccines.
- Cancer Prevention Program: The company's first cancer prevention program, mRNA-4194, aimed at patients with Lynch syndrome, has garnered investor attention, showcasing its innovative potential in the oncology field.
- Flu Vaccine Progress: An FDA advisory panel voted 9-0 in favor of the flu vaccine mRNA-1010 for adults aged 50 and older, with a final decision expected on August 5, 2026, further boosting market confidence in Moderna's future.
See More
Moderna Outlines Future Growth Plans at Science Day
- Future Growth Strategy: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Stephane Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, showcasing the company's forward-looking approach in vaccine development.
- Cancer Pipeline Progress: Moderna highlighted mRNA-4106 and mRNA-4200 for advanced solid tumors, along with mRNA-4194 targeting Lynch syndrome, which is the company's first cancer prevention study aimed at training the immune system to recognize 194 cancer-linked frameshift peptides, indicating potential for early intervention.
- Multiple Sclerosis Research: The mRNA-1195 program targets the Epstein-Barr virus, closely linked to multiple sclerosis, with the Phase 2 study fully enrolling its first group of patients, and an independent safety board recommending moving to dose escalation, suggesting initial safety and efficacy have been recognized.
- Flu Vaccine Regulatory Progress: Moderna's flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, indicating that its benefits outweigh risks for adults aged 50 and older, which is expected to provide an important new option for seasonal flu prevention and further solidify the company's position in the vaccine market.
See More
Moderna Outlines Future Growth Plans at Science Day
- Vaccine Development Focus: At Science Day, Moderna outlined its growth plans across infectious disease vaccines, Intismeran, and rare disease therapeutics, with CEO Bancel stating that Horizon 2 programs are already in the clinic and Horizon 3 programs are expected to enter human testing by the end of 2027, laying a solid foundation for future product line expansion.
- mRED Strategy Implementation: Moderna's mRED strategy aims to quickly test early 'sentinel' programs, promptly halt ineffective drugs, and accelerate promising ones, ensuring swift decision-making during the high-risk clinical development phase, thereby enhancing R&D efficiency and mitigating risks.
- Significant Cancer Pipeline Progress: Moderna highlighted its mRNA projects targeting various cancers, including mRNA-4106 and mRNA-4200, particularly mRNA-4194 as its first cancer prevention program aimed at training the immune system to recognize cancer-linked peptides, showcasing strong market potential for early disease targeting.
- AI Technology Enhancing R&D: Moderna introduced its Scientific Intelligence Engine, Lucy, emphasizing the scientific advantage of rapid learning, while its flu vaccine candidate mRNA-1010 received a 9-0 vote of support from the FDA advisory committee, expected to provide an important new option for seasonal flu prevention, further strengthening the company's competitive position.
See More
Biotech Stocks Hit 52-Week Highs Amid Speculation and Trials
- Sellas Life Sciences Surge: Sellas Life Sciences' stock soared 17% to a 52-week high of $12.43 as record short interest and acquisition speculation fueled investor optimism, particularly ahead of a key update from its Phase 3 AML trial.
- Moderna's Pipeline Advances: Moderna's stock rose 12% to $69.29 following its Science Day presentation, where it showcased advancements in cancer, autoimmune, and rare disease therapies, emphasizing its strategic use of AI and automation in drug discovery.
- AbCellera's Major Partnership: AbCellera Biologics' stock climbed over 10% to a two-year high of $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market confidence in their T-cell engager antibody programs.
- Investor Sentiment Optimism: The closing highs for Sellas Life Sciences, Moderna, and AbCellera Biologics on Friday reflect robust investor confidence in biotech firms, particularly those with identifiable near-term clinical events and business catalysts.
See More
Sellas Life Sciences Hits 52-Week High Amid Buyout Speculation
- Stock Surge: Sellas Life Sciences' stock reached a 52-week high of $12.43 on Friday, driven by record short interest and rising acquisition speculation, reflecting strong investor confidence in the company.
- Clinical Trial Update: The company is approaching a key update for its acute myeloid leukemia (AML) clinical trial, with 78 patient deaths recorded, just shy of the final analysis, which is eagerly anticipated by investors.
- Moderna's Innovations: Moderna's stock climbed to $69.29 following its Science Day presentation, showcasing advancements in cancer, autoimmune, and rare disease therapies, while emphasizing its use of AI and automation in drug discovery, solidifying its market position.
- AbCellera Partnership: AbCellera Biologics' stock rose to $7.40 due to its research collaboration with Jazz Pharmaceuticals, which includes $56 million in upfront funding, indicating strong market interest in its multispecific T-cell engager antibodies and potential future milestone payments.
See More
Moderna's Investor Day Sparks Surge in Stock Price
- Moderna Stock Surge: Moderna's stock has surged following its Investor Day, where the company outlined its future strategies beyond the COVID vaccine business, becoming a top performer in the S&P 500, indicating strong market confidence in its next-generation autoimmune disease treatments.
- Netflix Bounce Back: Netflix's stock is experiencing a relief bounce after hitting a 20-month low, as investors, despite concerns over competition and engagement, appear to be stepping back in, reflecting a reassessment of the company's growth potential.
- ON Semiconductor Acquisition: ON Semiconductor's shares are plummeting after announcing a nearly $7 billion all-stock deal to acquire Synaptics, aimed at expanding its push into physical AI, although investors are digesting the implications of this significant acquisition.
- Market Reaction Insights: The stock movements of Moderna and Netflix illustrate differing investor sentiments regarding future strategies, highlighting the critical importance of how companies adapt their business models to navigate current economic challenges.
See More
Moderna Shares Surge 42% as Company Expands Beyond COVID Vaccines
- Stock Surge: Moderna shares surged nearly 15% on Friday to around $69, marking a 42% increase over the past month, significantly outperforming the S&P 500's 7.49% return, reflecting strong market confidence in its future prospects.
- Diversification Strategy: During its Science Day event, Moderna highlighted progress in cancer treatments, autoimmune diseases, and next-generation mRNA medicines, indicating its commitment to becoming a diversified drug developer beyond COVID vaccines.
- Cancer Prevention Program: The company's first cancer prevention program, mRNA-4194, aimed at patients with Lynch syndrome, has garnered investor attention, showcasing its innovative potential in the oncology field.
- Flu Vaccine Progress: An FDA advisory panel voted 9-0 in favor of the flu vaccine mRNA-1010 for adults aged 50 and older, with a final decision expected on August 5, 2026, further boosting market confidence in Moderna's future.
See More
